Jump to content

Herpes: Difference between revisions

This is a good article. Click here for more information.
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→Research: changed the link for ribozyme to link for hammerhead ribozyme
Sleepeeg3 (talk | contribs)
129 edits
→Prevention: The source cited stated 11%
Line 211: Line 211:
[[Image:Kondom.jpg|thumb|Barrier protection, such as a [[condom]], can reduce the risk of herpes transmission.]]
[[Image:Kondom.jpg|thumb|Barrier protection, such as a [[condom]], can reduce the risk of herpes transmission.]]


As with almost all sexually transmitted infections, women are more susceptible to acquiring genital HSV-2 than men.<ref>{{cite news | author=Carla K. Johnson | title=Percentage of people with herpes drops | url=http://www.aegis.com/news/ap/2006/ap060840.html|accessdate=2011-04-12 | agency=Associated Press | date= August 23, 2006}}</ref> On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is approximately 8-10%.<ref name=Mertz1993>{{cite journal
As with almost all sexually transmitted infections, women are more susceptible to acquiring genital HSV-2 than men.<ref>{{cite news | author=Carla K. Johnson | title=Percentage of people with herpes drops | url=http://www.aegis.com/news/ap/2006/ap060840.html|accessdate=2011-04-12 | agency=Associated Press | date= August 23, 2006}}</ref> On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is approximately 8-11%.<ref name=Mertz1993>{{cite journal
|author=Mertz GJ |title=Epidemiology of genital herpes infections |journal=Infect Dis Clin North Am. |volume=7 |issue=4 |pages=825–39 |year=1993 |month=December |pmid=8106731
|author=Mertz GJ |title=Epidemiology of genital herpes infections |journal=Infect Dis Clin North Am. |volume=7 |issue=4 |pages=825–39 |year=1993 |month=December |pmid=8106731
}}</ref><ref name=Kulhanjian1992>{{cite journal
}}</ref><ref name=Kulhanjian1992>{{cite journal

Revision as of 07:46, 8 November 2011

"Herpes" redirects here. For the virus that causes herpes simplex, see Herpes simplex virus. For all types of herpes viruses, see Herpesviridae.
Herpes
SpecialtyInfectious diseases, dermatology Edit this on Wikidata

Herpes simplex (Template:Lang-grc, lit. "creeping") is a viral disease caused by both Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection. Oral herpes, the visible symptoms of which are colloquially called cold sores or fever blisters, infects the face and mouth. Oral herpes is the most common form of infection. Genital herpes, known simply as herpes, is the second most common form of herpes. Other disorders such as herpetic whitlow, herpes gladiatorum, ocular herpes (keratitis), cerebral herpes infection encephalitis, Mollaret's meningitis, neonatal herpes, and possibly Bell's palsy are all caused by herpes simplex viruses.

Herpes viruses cycle between periods of active disease—presenting as blisters containing infectious virus particles—that last 2–21 days, followed by a remission period. Genital herpes, however, is often asymptomatic, though viral shedding may still occur. After initial infection, the viruses are transported along sensory nerves to the sensory nerve cell bodies, where they become latent and reside life-long. Causes of recurrence are uncertain, though some potential triggers have been identified, including immunosuppressant drugs (see below). The previously latent virus then multiplies new virus particles in the nerve cell and these are transported along the axon of each neuron to the nerve terminals in the skin, where they are released. Over time, episodes of active disease reduce in frequency and severity.

Herpes simplex is most easily transmitted by direct contact with a lesion or the body fluid of an infected individual. Transmission may also occur through skin-to-skin contact during periods of asymptomatic shedding. Barrier protection methods are the most reliable method of preventing transmission of herpes, but they merely reduce rather than eliminate risk. Oral herpes is easily diagnosed if the patient presents with visible sores or ulcers. Early stages of orofacial herpes and genital herpes are harder to diagnose; laboratory testing is usually required.

A cure for herpes has not yet been developed. Once infected, the virus remains in the body for life. Recurrent infections (outbreaks) may occur from time to time, especially in times of immune impairment such as HIV and cancer-related immune suppression.[1] However, after several years, some people will become perpetually asymptomatic and will no longer experience outbreaks, though they may still be contagious to others. Treatments with antivirals can reduce viral shedding and alleviate the severity of symptomatic episodes. Vaccines are in clinical trials but have not demonstrated effectiveness. It should not be confused with conditions caused by other viruses in the herpesviridae family such as herpes zoster, which is caused by varicella zoster virus. The differential diagnosis includes hand, foot and mouth disease due to similar lesions on the skin.

Classification

Herpes simplex is divided into two types: HSV type 1 and HSV type 2.[2] HSV1 primarily causes mouth, throat, face, eye, and central nervous system infections, while HSV2 primarily causes anogenital infections.[2] However, each may cause infections in all areas.[2]

Signs and symptoms

HSV infection causes several distinct medical disorders. Common infection of the skin or mucosa may affect the face and mouth (orofacial herpes), genitalia (genital herpes), or hands (herpetic whitlow). More serious disorders occur when the virus infects and damages the eye (herpes keratitis), or invades the central nervous system, damaging the brain (herpes encephalitis). Patients with immature or suppressed immune systems, such as newborns, transplant recipients, or AIDS patients are prone to severe complications from HSV infections. HSV infection has also been associated with cognitive deficits of bipolar disorder,[3] and Alzheimer's disease,[4] although this is often dependent on the genetics of the infected person.

In all cases HSV is never removed from the body by the immune system. Following a primary infection, the virus enters the nerves at the site of primary infection, migrates to the cell body of the neuron, and becomes latent in the ganglion.[5] As a result of primary infection, the body produces antibodies to the particular type of HSV involved, preventing a subsequent infection of that type at a different site. In HSV-1 infected individuals, seroconversion after an oral infection will prevent additional HSV-1 infections such as whitlow, genital herpes, and keratitis. Prior HSV-1 seroconversion seems to reduce the symptoms of a later HSV-2 infection, although HSV-2 can still be contracted. Most indications are that an HSV-2 infection contracted prior to HSV-1 seroconversion will also immunize that person against HSV-1 infection.[citation needed]

Many people infected with HSV-2 display no physical symptoms—individuals with no symptoms are described as asymptomatic or as having subclinical herpes.[6]

Condition Description Illustration
Herpetic gingivostomatitis Herpetic gingivostomatitis is often the initial presentation during the first herpes infection. It is of greater severity than herpes labialis which is often the subsequent presentations.
Herpes labialis Infection occurs when the virus comes into contact with oral mucosa or abraded skin.
Herpes genitalis When symptomatic, the typical manifestation of a primary HSV-1 or HSV-2 genital infection is clusters of inflamed papules and vesicles on the outer surface of the genitals resembling cold sores.
Herpetic whitlow Herpes whitlow is a painful infection that typically affects the fingers or thumbs. Occasionally infection occurs on the toes or on the nail cuticle.
Herpes gladiatorum Individuals that participate in contact sports such as wrestling, rugby, and soccer sometimes acquire a condition caused by HSV-1 known as herpes gladiatorum, scrumpox, wrestler’s herpes, or mat herpes, which presents as skin ulceration on the face, ears, and neck. Symptoms include fever, headache, sore throat and swollen glands. It occasionally affects the eyes or eyelids.
Herpetic keratoconjunctivitis Primary infection typically presents as swelling of the conjunctiva and eyelids (blepharoconjunctivitis), accompanied by small white itchy lesions on the surface of the cornea.
Herpesviral encephalitis A herpetic infection of the brain that is thought to be caused by the retrograde transmission of virus from a peripheral site on the face following HSV-1 reactivation, along the trigeminal nerve axon, to the brain. HSV is the most common cause of viral encephalitis. When infecting the brain, the virus shows a preference for the temporal lobe.[7]
Herpesviral meningitis HSV-2 is the most common cause of Mollaret's meningitis, a type of recurrent viral meningitis.
Neonatal herpes simplex Neonatal HSV infection is a rare but serious condition, usually caused by vertical transmission of HSV (type 1 or 2) from mother to newborn.
During immunodeficiency In patients with a weakened immune system, herpes simplex can cause unusual lesions in the skin. One of the most striking is the appearance of clean linear erosions in skin creases, with the appearance of a knife cut.[8]
Herpetic sycosis Herpetic sycosis is a recurrent or initial herpes simplex infection affecting primarily the hair follicle.[9]: 369 
Eczema herpeticum Infection with herpesvirus in patients with chronic atopic dermatitis may result in spread of herpes simples throughout the eczematous areas.[9]: 373 
Herpes esophagitis Symptoms may include painful swallowing (odynophagia) and difficulty swallowing (dysphagia). It is often associated with impaired immune function (e.g. HIV/AIDS, immunosuppression in solid organ transplants).

Bell's palsy

Although the exact cause of Bell's palsy, a type of facial paralysis, is unknown it may be related to reactivation of herpes simplex virus type 1.[10] This theory has been contested, however since HSV is detected in large numbers of individuals who never experienced facial paralysis, and higher levels of antibodies for HSV are not found in HSV-infected individuals with Bell's palsy compared to those without.[11] Regardless antivirals have been found to not improve outcomes.[12]

Alzheimer's disease

HSV-1 has been proposed as a possible cause of Alzheimer's disease.[13][14] In the presence of a certain gene variation (APOE-epsilon4 allele carriers), HSV-1 appears to be particularly damaging to the nervous system and increases one’s risk of developing Alzheimer’s disease. The virus interacts with the components and receptors of lipoproteins, which may lead to the development of Alzheimer's disease.[15][16] Without the presence of the gene allele, HSV type 1 does not appear to cause any neurological damage and thus increase the risk of Alzheimer’s.[4] Herpes simplex virus type 1 DNA is localized within the beta-amyloid plaques that characterize Alzheimer's disease.[17] It suggests that this virus is a major cause of the plaques and hence probably a significant aetiological factor in Alzheimer's disease.

Pathophysiology

Herpes is contracted through direct contact with an active lesion or body fluid of an infected person.[18] Herpes transmission occurs between discordant partners; a person with a history of infection (HSV seropositive) can pass the virus to an HSV seronegative person. The only way to contract Herpes simplex virus 2 is through direct skin-to-skin contact with an infected individual.[citation needed] To infect a new individual, HSV travels through tiny breaks in the skin or mucous membranes in the mouth or genital areas. Even microscopic abrasions on mucous membranes are sufficient to allow viral entry.

Herpes Shedding[19]
HSV-2 genital 15-25% of days
HSV-1 oral 6-33% of days
HSV-1 genital 5% of days
HSV-2 oral 1% of days

HSV asymptomatic shedding occurs at some time in most individuals infected with herpes. It can occur more than a week before or after a symptomatic recurrence in 50% of cases.[20] Virus enters into susceptible cells via entry receptors[21] such as nectin-1, HVEM and 3-O sulfated heparan sulfate.[22] Infected people that show no visible symptoms may still shed and transmit virus through their skin; asymptomatic shedding may represent the most common form of HSV-2 transmission.[20] Asymptomatic shedding is more frequent within the first 12 months of acquiring HSV. Concurrent infection with HIV increases the frequency and duration of asymptomatic shedding.[23] There are indications that some individuals may have much lower patterns of shedding, but evidence supporting this is not fully verified; no significant differences are seen in the frequency of asymptomatic shedding when comparing persons with one to twelve annual recurrences to those who have no recurrences.[20]

Antibodies that develop following an initial infection with a type of HSV prevents reinfection with the same virus type—a person with a history of orofacial infection caused by HSV-1 cannot contract herpes whitlow or a genital infection caused by HSV-1. In a monogamous couple, a seronegative female runs a greater than 30% per year risk of contracting an HSV infection from a seropositive male partner.[24] If an oral HSV-1 infection is contracted first, seroconversion will have occurred after 6 weeks to provide protective antibodies against a future genital HSV-1 infection.

Diagnosis

Primary orofacial herpes is readily identified by clinical examination of persons with no previous history of lesions and contact with an individual with known HSV-1 infection. The appearance and distribution of sores in these individuals typically presents as multiple, round, superficial oral ulcers, accompanied by acute gingivitis.[25] Adults with non-typical presentation are more difficult to diagnose. Prodromal symptoms that occur before the appearance of herpetic lesions help differentiate HSV symptoms from the similar symptoms of other disorders, such as allergic stomatitis. When lesions do not appear inside the mouth, primary orofacial herpes is sometimes mistaken for impetigo, a bacterial infection. Common mouth ulcers (aphthous ulcer) also resemble intraoral herpes, but do not present a vesicular stage.[25]

Genital herpes can be more difficult to diagnose than oral herpes since most HSV-2-infected persons have no classical symptoms.[25] Further confusing diagnosis, several other conditions resemble genital herpes, including fungal infection, lichen planus, atopic dermatitis, and urethritis.[25] Laboratory testing is often used to confirm a diagnosis of genital herpes. Laboratory tests include: culture of the virus, direct fluorescent antibody (DFA) studies to detect virus, skin biopsy, and polymerase chain reaction (PCR) to test for presence of viral DNA. Although these procedures produce highly sensitive and specific diagnoses, their high costs and time constraints discourage their regular use in clinical practice.[25]

Until recently, serological tests for antibodies to HSV were rarely useful to diagnosis and not routinely used in clinical practice.[25] The older IgM serologic assay could not differentiate between antibodies generated in response to HSV-1 or HSV-2 infection. However, the new Immunodot glycoprotein G-specific (IgG) HSV test is more than 98% specific at discriminating HSV-1 from HSV-2.[26] It is the opinion of some modern medical professionals that the new IgG test should always be clinically preferred to the old IgM test, however not all doctors appear to be informed of the availability of the newer, reliable IgG tests.[27]

Prevention

Barrier protection, such as a condom, can reduce the risk of herpes transmission.

As with almost all sexually transmitted infections, women are more susceptible to acquiring genital HSV-2 than men.[28] On an annual basis, without the use of antivirals or condoms, the transmission risk of HSV-2 from infected male to female is approximately 8-11%.[24][29] This is believed to be due to the increased exposure of mucosal tissue to potential infection sites. Transmission risk from infected female to male is approximately 4-5% annually.[29] Suppressive antiviral therapy reduces these risks by 50%.[30] Antivirals also help prevent the development of symptomatic HSV in infection scenarios—meaning the infected partner will be seropositive but symptom free—by about 50%. Condom use also reduces the transmission risk by 50%.[31][32][33] Condom use is much more effective at preventing male to female transmission than vice-versa.[31] The effects of combining antiviral and condom use is roughly additive, thus resulting in approximately a 75% combined reduction in annual transmission risk.[citation needed] These figures reflect experiences with subjects having frequently recurring genital herpes (>6 recurrences per year). Subjects with low recurrence rates and those with no clinical manifestations were excluded from these studies.[citation needed] Previous HSV-1 infection appears to reduce the risk for acquisition of HSV-2 infection among women by a factor of 3.[34]

However, asymptomatic carriers of the HSV-2 virus are still contagious. In many infections, the first symptom a person will have of their own infection is the horizontal transmission to a sexual partner or the vertical transmission of neonatal herpes to a newborn at term. Since most asymptomatic individuals are unaware of their infection, they are considered at high risk for spreading HSV.[citation needed]

In October 2011, it was reported that the anti-HIV drug tenofovir, when used topically in a microbicidal vaginal gel, prevented herpes virus infections.[35]

Barrier methods

Condoms offer moderate protection against HSV-2 in both men and women, with consistent condom users having a 30% lower risk of HSV-2 acquisition compared with those who never use condoms.[36] A female condom can provide greater protection than the male condom, as it covers the labia.[37] The virus cannot pass through a synthetic condom, but a male condom's effectiveness is limited[38] because herpes ulcers may appear on areas not covered by the male condom. Neither type of condom prevents contact with the scrotum, anus, buttocks, or upper thighs, areas which may come in contact with ulcers or genital secretions during sexual activity. Protection against herpes simplex depends on the site of the ulcer; therefore if ulcers appear on areas not covered by condoms, abstaining from sexual activity until the ulcers are fully healed is one way to limit risk of transmission.[39] The risk is not eliminated, however, as viral shedding capable of transmitting infection may still occur while the infected partner is asymptomatic.[40] The use of condoms or dental dams also limits the transmission of herpes from the genitals of one partner to the mouth of the other (or vice versa) during oral sex. When one partner has a herpes simplex infection and the other does not, the use of antiviral medication, such as valaciclovir, in conjunction with a condom further decreases the chances of transmission to the uninfected partner.[5] Topical microbicides which contain chemicals that directly inactivate the virus and block viral entry are being investigated.[5]

Vaccine

Vaccines for HSV are undergoing trials. Once developed, they may be used to help with prevention or minimize initial infections as well as treatment for existing infections.[41]

Antivirals

Antivirals may reduce asymptomatic shedding; it is believed asymptomatic genital HSV-2 viral shedding occurs on 20% of days per year in patients not undergoing antiviral treatment, versus 10% of days while on antiviral therapy.[20]

Pregnancy

The risk of transmission from mother to baby is highest if the mother becomes infected at around the time of delivery (30% to 60%),[42][43] but the risk falls to 3% if it is a recurrent infection, and is less than 1% if there are no visible lesions.[44] To prevent neonatal infections, seronegative women are recommended to avoid unprotected oral-genital contact with an HSV-1 seropositive partner and conventional sex with a partner having a genital infection during the last trimester of pregnancy. A seronegative mother who contracts HSV at this time has up to a 57% chance of conveying the infection to her baby during childbirth, since insufficient time will have occurred for the generation and transfer of protective maternal antibodies before the birth of the child, whereas a woman seropositive for both HSV-1 and HSV-2 has around a 1-3% chance of transmitting infection to her infant.[45][46] Women who are seropositive for only one type of HSV are only half as likely to transmit HSV as infected seronegative mothers. Mothers infected with HSV are advised to avoid procedures that would cause trauma to the infant during birth (e.g. fetal scalp electrodes, forceps, and vacuum extractors) and, should lesions be present, to elect caesarean section to reduce exposure of the child to infected secretions in the birth canal.[5] The use of antiviral treatments, such as acyclovir, given from the 36th week of pregnancy, limits HSV recurrence and shedding during childbirth, thereby reducing the need for caesarean section.[5]

Acyclovir is the recommended antiviral for herpes suppressive therapy during the last months of pregnancy. The use of valaciclovir and famciclovir, while potentially improving compliance have less well determined safety in pregnancy.

Treatment

There is no method to eradicate herpes virus from the body, but antiviral medications can reduce the frequency, duration, and severity of outbreaks. Analgesics such as ibuprofen and acetaminophen can reduce pain and fever. Topical anesthetic treatments such as prilocaine, lidocaine, benzocaine or tetracaine can also relieve itching and pain.[47][48][49]

Antiviral

The antiviral medication acyclovir

There are several antivirals that are effective for treating herpes including: aciclovir (acyclovir), valaciclovir (valacyclovir), famciclovir, and penciclovir. Aciclovir was the first discovered and is now available in generic.

Evidence supports the use of aciclovir and valaciclovir in the treatment of herpes labialis[50] as well as herpes infections in people with cancer.[51] The evidence to support the use of acyclovir in primary herpetic gingivostomatitis is less strong.[52]

Topical

A number of topical antivirals are effective for herpes labialis including acyclovir, penciclovir, and docosanol.[50][53] Docosanol can be purchased over the counter in Canada and the USA.

Alternative medicine

Certain dietary supplements and alternative remedies are claimed to be beneficial in the treatment of herpes. There is however insufficient evidence to support use of many of these compounds including echinacea, eleuthero, L-lysine, zinc, bee products and aloe vera.[54]

A single study indicates possible benefit from laser treatment.[55]

Prognosis

Following active infection, herpes viruses establish a latent infection in sensory and autonomic ganglia of the nervous system. The double-stranded DNA of the virus is incorporated into the cell physiology by infection of the nucleus of a nerve's cell body. HSV latency is static—no virus is produced—and is controlled by a number of viral genes, including Latency Associated Transcript (LAT).[56]

Many HSV-infected people experience recurrence within the first year of infection.[5] Prodrome precedes development of lesions. Prodromal symptoms include tingling (paresthesia), itching, and pain where lumbosacral nerves innervate the skin. Prodrome may occur as long as several days or as short as a few hours before lesions develop. Beginning antiviral treatment when prodrome is experienced can reduce the appearance and duration of lesions in some individuals. During recurrence, fewer lesions are likely to develop, lesions are less painful and heal faster (within 5–10 days without antiviral treatment) than those occurring during the primary infection.[5] Subsequent outbreaks tend to be periodic or episodic, occurring on average four to five times a year when not using antiviral therapy.

The causes of reactivation are uncertain, but several potential triggers have been documented. A recent study (2009) showed that the protein VP16 plays a key role in reactivation of the dormant virus.[57] Changes in the immune system during menstruation may play a role in HSV-1 reactivation.[58][59] Concurrent infections, such as viral upper respiratory tract infection or other febrile diseases, can cause outbreaks. Reactivation due to infection is the likely source of the historic terms cold sore and fever blister.

Other identified triggers include: local injury to the face, lips, eyes, or mouth, trauma, surgery, radiotherapy, and exposure to wind, ultraviolet light, or sunlight.[60][61][62][63][64]

The frequency and severity of recurrent outbreaks vary greatly between patients. Some individuals' outbreaks can be quite debilitating with large, painful lesions persisting for several weeks, while others will experience only minor itching or burning for a few days. There is some evidence that genetics plays a role in the frequency of cold sore outbreaks. An area of human chromosome 21 that includes 6 genes has been linked to frequent oral herpes outbreaks. An immunity to the virus is built over time. Most infected individuals will experience fewer outbreaks and outbreak symptoms will often become less severe. After several years, some people will become perpetually asymptomatic and will no longer experience outbreaks, though they may still be contagious to others. Immuno-compromised individuals may experience episodes that are longer, more frequent, and more severe. Antiviral medication has been proven to shorten the frequency and duration of outbreaks.[65] Outbreaks may occur at the original site of the infection or in proximity to nerve endings that reach out from the infected ganglia. In the case of a genital infection, sores can appear at the original site of infection or near the base of the spine, the buttocks, or the back of the thighs. HSV-2 infected individuals are at higher risk for acquiring HIV when practicing unprotected sex with HIV-positive persons,[66] particularly during an outbreak with active lesions.[67]

Epidemiology

Main article: Epidemiology of herpes simplex

Worldwide rates of HSV infection are between 65% and 90%.[2] HSV1 is more common than HSV2 with rates of both increasing as people age.[2] Rates of infection are determined by the presence of antibodies against either viral species.[68]

In the US, 57.7% of the population is infected with HSV-1[69] and 16.2% are infected with HSV-2. Among those HSV-2 seropositive, only 18.9% were aware that they were infected.[70]

History

Herpes has been known for at least 2,000 years. It is said that Emperor Tiberius banned kissing in Rome for a time due to so many people having cold sores. In the 16th century Romeo and Juliet, it is mentioned that there are blisters "o'er ladies' lips." In 18th century it was so common among prostitutes that it was called "a vocational disease of women."[71]

The term Herpes Simplex appeared in Richard Boulton's A System of Rational and Practical Chirurgery in 1713, where the terms Herpes miliaris and Herpes exedens also appeared.

Herpes was not found to be a virus until the 1940s.[71]

Herpes antiviral therapy began in the early 1960s with the experimental use of medication that interfered with viral replication called deoxyribonucleic acid (DNA) inhibitors. The original use was against normally fatal or disabilitating illness such as adult encephalitis,[72] keratitis,[73] in immunocompromised (transplant) patients,[74] or disseminated herpes zoster.[75] The original compounds used were 5-iodo-2'-deoxyuridine, AKA idoxuridine, IUdR, or(IDU) and 1-β-D-arabinofuranosylcytosine or ara-C,[76] later marketed under the name cytosar or cytorabine. The usage expanded to include topical treatment of herpes simplex,[77] zoster, and varicella.[78] Some trials combined different antivirals with differing results.[72] The introduction of 9-β-D-arabinofuranosyladenine, AKA ara-A or vidarabine, considerably less toxic than Ara-C, in the mid 1970s, heralded the way for the beginning of regular neonatal antiviral treatment. Vidarabine was the first systemically administered antiviral medication with activity against HSV for which therapeutic efficacy outweighed toxicity for the management of life-threatening HSV disease. Intravenous vidarabine was licensed for use by the U.S. Food and Drug Administration (FDA) in 1977. Other experimental antivirals of that period included: Heparin,[79] trifluorothymidine (TFT),[80] Ribivarin,[81] interferon,[82] Virazole,[83] and 5-methoxymethyl-2'-deoxyuridine (MMUdR).[84] The introduction of 9-(2-hydroxyethoxymethyl)guanine, AKA acyclovir, in the late 1970s[85] raised antiviral treatment another notch and led to vidarabine vs. acyclovir trials in the late 1980s.[86] The lower toxicity and ease of administration over vidarabine has led to acyclovir becoming the drug of choice for herpes treatment after it was licensed by the FDA in 1998.[87] Another advantage in the treatment of neonatal herpes included greater reductions in mortality and morbidity with increased dosages, something that did not occur when compared with increased dosages of vidarabine.[87] On the other side of the equation, acyclovir seems to inhibit antibody response and newborns on acyclovir antiviral treatment experienced a slower rise in antibody titer than those on vidarabine.[87]

Society and culture

Herpes simplex was not always stigmatised. It was merely a cold sore in an unusual place until the 1970s. As late as 1975, a study of “Psychological morbidity in a clinic for sexually-transmitted disease” (Richard Mayou, The London Hospital)[88] does not mention herpes simplex because at that time, there was no significant morbidity problem (i.e. mental anxiety or illness) associated with the virus.

In the Journal of Clinical Investigation,[89] Pedro Cuatrecasas states, “during the R&D of acyclovir (Zovirax), marketing [department of Burroughs Wellcome] insisted that there were ‘no markets’ for this compound. Most had hardly heard of genital herpes...” Thus marketing the medical condition – separating the ‘normal cold sore’ from the ‘stigmatized genital infection’ was to become the key to marketing the drug, a process now known as ‘disease mongering’.[90]

Since the creation of the herpes hype, some people experience negative feelings related to the condition following diagnosis, particularly if they have acquired the genital form of the disease. Feelings can include depression, fear of rejection, feelings of isolation, fear of being found out, self-destructive feelings, and fear of masturbation.[91] These feelings usually lessen over time. Much of the hysteria and stigma surrounding herpes stems from a media campaign beginning in the late 1970s and peaking in the early 1980s. There were multiple articles worded in fear-mongering and anxiety-provoking terminology, such as the now ubiquitous "attacks," "outbreaks," "victims," and "sufferers." At one point the term "herpetic" even entered the popular lexicon. The articles were published by Reader's Digest, U.S. News, and Time magazine, among others. A made-for-TV movie was named Intimate Agony. The peak was when Time magazine had 'Herpes: The New Scarlet Letter' on the cover in August 1982, forever stigmatizing the word in the public mind.[71] The scientific reality is that most people are asymptomatic, the virus causes no real health problems for a vast majority of people, and a vast majority (around 90%) of the Earth's population carries HSV-1, 2, or both.[92][93] Herpes support groups have been formed in the United States and the UK, providing information about herpes and running message forums and dating websites for "sufferers." People with the herpes virus are often hesitant to divulge to other people, including friends and family, that they are infected. This is especially true of new or potential sexual partners whom they consider casual.[94]

Research

Researchers at the University of Florida have made a Hammerhead ribozyme that targets and cleaves the mRNA of essential genes in HSV-1. The hammerhead which targets the mRNA of the UL20 gene greatly reduced the level of HSV-1 ocular infection in rabbits and reduced the viral yield in vivo.[95] The gene-targeting approach uses a specially designed RNA enzyme to inhibit strains of the herpes simplex virus. The enzyme disables a gene responsible for producing a protein involved in the maturation and release of viral particles in an infected cell. The technique appears to be effective in experiments with mice and rabbits, but further research is required before it can be attempted in people who are infected with herpes.[96]

Another possibility to eradicate the HSV-1 variant is being pursued by a team at Duke University. By figuring out how to switch all copies of the virus in the host from latency to their active stage at the same time, rather than the way the virus copies normally stagger their activity stage, leaving some dormant somewhere at all times, it is thought that conventional anti-viral drugs can kill the entire virus population completely, since they can no longer hide in the nerve cells. One class of drugs called antagomir could serve this purpose. These are chemically engineered oligonucleotides or short segments of RNA, that can be made to mirror their target genetic material, namely herpes microRNAs. They could be engineered to attach and thus 'silence' the microRNA, thus rendering the virus incapable to keep latent in their host.[97] Professor Cullen believes a drug could be developed to block the microRNA whose job it is to suppress HSV-1 into latency.[98]

One vaccine that was under trial was Herpevac, a vaccine against HSV-2. The National Institutes of Health (NIH) in the United States conducted phase III trials of Herpevac.[99] In 2010, it was reported that, after 8 years of study in more than 8000 women in the United States and Canada, there was no sign of positive results against the sexually transmitted disease caused by HSV-2[100] (and this despite earlier favorable interim reports[99]).

A laboratory at Harvard Medical School has developed dl5-29 (now known as ACAM-529), a replication-defective mutant virus that has proved successful both in preventing HSV-2/HSV-1 infections, and in combating the virus in already infected hosts, in animal models. It has been shown that the replication-defective vaccine induces strong HSV-2-specific antibody and T-cell responses; protects against challenge with a wild-type HSV-2 virus; greatly reduces the severity of recurrent disease; provides cross-protection against HSV-1, and renders the virus unable to revert to a virulent state or to become latent.[101] His vaccine is now being researched and developed by Accambis (acquired by Sanofi Pasteur in September 2008), and is due to be applied as an Investigational New Drug in 2009.[102] However, the status of ACAM-529 became after the acquisition somewhat unclear. According to Jim Tartaglia, a company representative of Sanofi Pasteur, ACAM-529 is still under development and should be enter phase I clinical testing in 2012.[103]

A private company called BioVex began Phase I clinical trials for ImmunoVEX, another proposed vaccine, in March 2010.[104] A completely new approach has the "HSV-2 ICP0 live-attenuated HSV-2 vaccine" investigated by Dr. William Halford at the Southern Illinois University (SIU) School of Medicine.[105]

References

  1. ^ Elad S; Zadik Y; Hewson I; et al. (2010). "A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea". Support Care Cancer. 18 (8): 993–1006. doi:10.1007/s00520-010-0900-3. PMID 20544224. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  2. ^ a b c d e Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF (2009). "Herpes simplex". Pediatr Rev. 30 (4): 119–29, quiz 130. doi:10.1542/pir.30-4-119. PMID 19339385. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Dickerson FB; Boronow JJ; Stallings C; et al. (2004). "Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder". Biol. Psychiatry. 55 (6): 588–93. doi:10.1016/j.biopsych.2003.10.008. PMID 15013827. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  4. ^ a b Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997). "Herpes simplex virus type 1 in brain and risk of Alzheimer's disease". Lancet. 349 (9047): 241–4. doi:10.1016/S0140-6736(96)10149-5. PMID 9014911. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ a b c d e f g Gupta R, Warren T, Wald A (2007). "Genital herpes". Lancet. 370 (9605): 2127–37. doi:10.1016/S0140-6736(07)61908-4. PMID 18156035. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Handsfield HH (2000). "Public Health Strategies to Prevent Genital Herpes: Where Do We Stand?". Curr Infect Dis Rep. 2 (1): 25–30. doi:10.1007/s11908-000-0084-y. PMID 11095834.
  7. ^ "Herpes Encephalitis: eMedicine Radiology".
  8. ^ Jocelyn A. Lieb, Stacey Brisman, Sara Herman, Jennifer MacGregor, Marc E. Grossman (2008). "Linear erosive Herpes Simplex Virus infection in immunocompromised patients: the "Knife-Cut Sign"". Clin Infect Dis. 47 (11): 1440–1441. doi:10.1086/592976. PMID 18937574.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ a b James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. {{cite book}}: Invalid |display-authors=3 (help)
  10. ^ Tankéré F, Bernat I (2009). "[Bell's palsy: from viral aetiology to diagnostic reality]". Rev Med Interne (in French). 30 (9): 769–75. doi:10.1016/j.revmed.2008.12.006. PMID 19195745. {{cite journal}}: Unknown parameter |month= ignored (help)
  11. ^ Linder T, Bossart W, Bodmer D (2005). "Bell's palsy and Herpes simplex virus: fact or mystery?". Otol. Neurotol. 26 (1): 109–13. doi:10.1097/00129492-200501000-00020. PMID 15699730. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  12. ^ Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F (2009). Lockhart, Pauline (ed.). "Antiviral treatment for Bell's palsy (idiopathic facial paralysis)". Cochrane Database Syst Rev (4): CD001869. doi:10.1002/14651858.CD001869.pub4. PMID 19821283.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Itzhaki RF, Wozniak MA (2008). "Herpes simplex virus type 1 in Alzheimer's disease: the enemy within". J. Alzheimers Dis. 13 (4): 393–405. PMID 18487848. {{cite journal}}: Unknown parameter |month= ignored (help)
  14. ^ Holmes C, Cotterell D (2009). "Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment". CNS Drugs. 23 (12): 993–1002. doi:10.2165/11310910-000000000-00000. PMID 19958038. {{cite journal}}: Unknown parameter |month= ignored (help)
  15. ^ Dobson CB, Itzhaki RF (1999). "Herpes simplex virus type 1 and Alzheimer's disease". Neurobiol. Aging. 20 (4): 457–65. doi:10.1016/S0197-4580(99)00055-X. PMID 10604441.
  16. ^ This research identifies HSVs as the pathogen most clearly linked to the 2001Pyles RB (2001). "The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors" (PDF). Herpes. 8 (3): 64–8. PMID 11867022. {{cite journal}}: Unknown parameter |month= ignored (help)
  17. ^ Wozniak MA, Mee AP, Itzhaki RF (2009). "Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques". J Pathol. 217 (1): 131–8. doi:10.1002/path.2449. PMID 18973185. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  18. ^ "AHMF: Preventing Sexual Transmission of Genital herpes". Archived from the original on January 21, 2008. Retrieved 2008-02-24.
  19. ^ Warren, Terri (2009). The Good News about the Bad News: Herpes: Everything You Need to Know. New Harbinger Publications. p. 28. ISBN 1572246189.
  20. ^ a b c d Leone P (2005). "Reducing the risk of transmitting genital herpes: advances in understanding and therapy". Curr Med Res Opin. 21 (10): 1577–82. doi:10.1185/030079905X61901. PMID 16238897.
  21. ^ Akhtar, Jihan; Shukla, Deepak. "Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry". FEBS Journal. 2009 (276).
  22. ^ Shukla, Deepak; Liu, Jian; Blaiklock, Peter; Shworak, Nicholas W.; Bai, Xiaomei; Esko, Jeffrey D.; Cohen, Gary H.; Eisenberg, Roselyn; Rosenberg, Robert D. (1999). "A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry". Cell. 99 (1): 13–22. doi:10.1016/S0092-8674(00)80058-6. PMID 10520990.
  23. ^ Kim H, Meier A, Huang M, Kuntz S, Selke S, Celum C, Corey L, Wald A (2006). "Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men". J Infect Dis. 194 (4): 420–7. doi:10.1086/505879. PMID 16845624.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  24. ^ a b Mertz, G.J. (1993). "Epidemiology of genital herpes infections". Infect Dis Clin North Am. 7 (4): 825–39. PMID 8106731. Cite error: The named reference "Mertz1993" was defined multiple times with different content (see the help page).
  25. ^ a b c d e f Fatahzadeh M, Schwartz RA (2007). "Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management". J. Am. Acad. Dermatol. 57 (5): 737–63, quiz 764–6. doi:10.1016/j.jaad.2007.06.027. PMID 17939933.
  26. ^ Ashley RL; et al. (1988). "Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera". J. Clin. Microbiol. 26 (4): 662–667. PMC 266403. PMID 2835389. {{cite journal}}: Explicit use of et al. in: |author= (help)
  27. ^ Warren, Terri (2009). The Good News About The Bad News. New Harbinger Publications. p. 209. ISBN 1572246189.
  28. ^ Carla K. Johnson (August 23, 2006). "Percentage of people with herpes drops". Associated Press. Retrieved 2011-04-12.
  29. ^ a b Kulhanjian JA; Soroush V; Au DS; et al. (April 2, 1992). "Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy". N. Engl. J. Med. 326 (14): 916–20. doi:10.1056/NEJM199204023261403. PMID 1311799. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  30. ^ Corey L; Wald A; Patel R; et al. (2004). "Once-daily valacyclovir to reduce the risk of transmission of genital herpes" (PDF). N Engl J Med. 350 (1): 11–20. doi:10.1056/NEJMoa035144. PMID 14702423. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  31. ^ a b Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, Tyring S, Douglas JM Jr, Corey L. (2001). "Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women". JAMA. 285 (24): 3100–3106. doi:10.1001/jama.285.24.3100. PMID 11427138.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Casper C, Wald A. (2002). "Condom use and the prevention of genital herpes acquisition," (PDF). Herpes. 9 (1): 10–14. PMID 11916494.
  33. ^ Wald A; Langenberg AG; Krantz E; et al. (2005). "The relationship between condom use and herpes simplex virus acquisition". Ann Intern Med. 143 (10): 707–13. PMID 16287791. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  34. ^ Mertz, GJ (01). "Risk factors for the sexual transmission of genital herpes". Annals of Internal Medicine. 116 (3): 197–202. PMID 1309413. {{cite journal}}: Check date values in: |date= and |year= / |date= mismatch (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  35. ^ McNeil DJ. http://www.nytimes.com/2011/10/21/health/research/21herpes.htmlTopical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. NY Times. Research article: Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication.
  36. ^ Emily T. Martin, MPH; Elizabeth Krantz, MS; Sami L. Gottlieb, MD, MSPH; Amalia S. Magaret, PhD; Andria Langenberg, MD; Lawrence Stanberry, MD, PhD; Mary Kamb, MD, MPH; Anna Wald, MD, MPH (2009). "A Pooled Analysis of the Effect of Condoms in Preventing HSV-2 Acquisition". Archives of Internal Medicine. 169 (13): 1233–1240. doi:10.1001/archinternmed.2009.177. PMC 2860381. PMID 19597073.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  37. ^ "Putting Herpes in Perspective". UBM Medica. Retrieved 20 July 2011.
  38. ^ "Condom Effectiveness - Male Latex Condoms and Sexually Transmitted Diseases". Center for Disease Control and Prevention. Retrieved October 2011. {{cite web}}: Check date values in: |accessdate= (help)
  39. ^ "STD Facts - Genital Herpes". Center for Disease Control and Prevention. Retrieved October 2011. {{cite web}}: Check date values in: |accessdate= (help)
  40. ^ Koelle, D.M. (2000). "Herpes simplex virus: The importance of asymptomatic shedding" (PDF). Journal of Antimicrobial Chemotherapy. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  41. ^ Seppa, Nathan (2005-01-05). "One-Two Punch: Vaccine fights herpes with antibodies, T cells". Science News. p. 5. Archived from the original on January 6, 2007. Retrieved 2007-03-29.
  42. ^ Brown ZA; Selke S; Zeh J; et al. (1997). "The acquisition of herpes simplex virus during pregnancy". N Engl J Med. 337 (8): 509–515. doi:10.1056/NEJM199708213370801. PMID 9262493. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  43. ^ Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L (2003). "Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant". JAMA. 289 (2): 203–209. doi:10.1001/jama.289.2.203. PMID 12517231.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  44. ^ Brown ZA; Benedetti J; Ashley R; et al. (1991). "Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor". N Engl J Med. 324 (18): 1247. doi:10.1056/NEJM199105023241804. PMID 1849612. {{cite journal}}: More than one of |pages= and |page= specified (help); Unknown parameter |author-separator= ignored (help)
  45. ^ Whitley RJ, Kimberlin DW, Roizman B (1998). "Herpes simplex viruses". Clin Infect Dis. 26 (3): 541–53. doi:10.1086/514600. PMID 9524821.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  46. ^ Brown ZA; Benedetti J; Ashley R; et al. (1991). "Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor". N. Engl. J. Med. 324 (18): 1247–52. doi:10.1056/NEJM199105023241804. PMID 1849612. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  47. ^ <Please add first missing authors to populate metadata.> (1988). "Local anesthetic creams". BMJ. 297 (6661): 1468. PMC 1835116. PMID 3147021. {{cite journal}}: Unknown parameter |month= ignored (help)
  48. ^ Kaminester LH; Pariser RJ; Pariser DM; et al. (1999). "A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis". J. Am. Acad. Dermatol. 41 (6): 996–1001. doi:10.1016/S0190-9622(99)70260-4. PMID 10570387. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  49. ^ Leung DT, Sacks SL (2003). "Current treatment options to prevent perinatal transmission of herpes simplex virus". Expert Opin Pharmacother. 4 (10): 1809–19. doi:10.1517/14656566.4.10.1809. PMID 14521490. {{cite journal}}: Unknown parameter |month= ignored (help)
  50. ^ a b Chon T, Nguyen L, Elliott TC (2007). "Clinical inquiries. What are the best treatments for herpes labialis?". J Fam Pract. 56 (7): 576–8. PMID 17605952. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  51. ^ Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009). Glenny, Anne-Marie (ed.). "Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer". Cochrane Database Syst Rev (1): CD006706. doi:10.1002/14651858.CD006706.pub2. PMID 19160295.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Nasser M, Fedorowicz Z, Khoshnevisan MH, Shahiri Tabarestani M (2008). Nasser, Mona (ed.). "Acyclovir for treating primary herpetic gingivostomatitis". Cochrane Database Syst Rev (4): CD006700. doi:10.1002/14651858.CD006700.pub2. PMID 18843726.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  53. ^ Treister NS, Woo SB (2010). "Topical n-docosanol for management of recurrent herpes labialis". Expert Opin Pharmacother. 11 (5): 853–60. doi:10.1517/14656561003691847. PMID 20210688. {{cite journal}}: Unknown parameter |month= ignored (help)
  54. ^ Perfect MM, Bourne N, Ebel C, Rosenthal SL (2005). "Use of complementary and alternative medicine for the treatment of genital herpes". Herpes. 12 (2): 38–41. PMID 16209859. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  55. ^ Hargate G (2006). "A randomised double-blind study comparing the effect of 1072-nm light against placebo for the treatment of herpes labialis". Clin. Exp. Dermatol. 31 (5): 638–41. doi:10.1111/j.1365-2230.2006.02191.x. PMID 16780494. {{cite journal}}: Unknown parameter |month= ignored (help)
  56. ^ Stumpf MP, Laidlaw Z, Jansen VA (2002). "Herpes viruses hedge their bets". Proc. Natl. Acad. Sci. U.S.A. 99 (23): 15234–7. doi:10.1073/pnas.232546899. PMC 137573. PMID 12409612.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  57. ^ "How Herpes Re-rears Its Ugly Head - Science News".
  58. ^ Myśliwska J, Trzonkowski P, Bryl E, Lukaszuk K, Myśliwski A (2000). "Lower interleukin-2 and higher serum tumor necrosis factor-a levels are associated with perimenstrual, recurrent, facial Herpes simplex infection in young women". Eur. Cytokine Netw. 11 (3): 397–406. PMID 11022124.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  59. ^ Segal AL, Katcher AH, Brightman VJ, Miller MF (1974). "Recurrent herpes labialis, recurrent aphthous ulcers, and the menstrual cycle". J. Dent. Res. 53 (4): 797–803. doi:10.1177/00220345740530040501. PMID 4526372.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  60. ^ Chambers A, Perry M (2008). "Salivary mediated autoinoculation of herpes simplex virus on the face in the absence of "cold sores," after trauma". J. Oral Maxillofac. Surg. 66 (1): 136–8. doi:10.1016/j.joms.2006.07.019. PMID 18083428.
  61. ^ Perna JJ, Mannix ML, Rooney JF, Notkins AL, Straus SE (1987). "Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model". J. Am. Acad. Dermatol. 17 (3): 473–8. doi:10.1016/S0190-9622(87)70232-1. PMID 2821086.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  62. ^ Rooney JF; Straus SE; Mannix ML; et al. (1992). "UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir". J. Infect. Dis. 166 (3): 500–6. doi:10.1093/infdis/166.3.500. PMID 1323616. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  63. ^ Oakley C, Epstein JB, Sherlock CH (1997). "Reactivation of oral herpes simplex virus: implications for clinical management of herpes simplex virus recurrence during radiotherapy". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 84 (3): 272–8. doi:10.1016/S1079-2104(97)90342-5. PMID 9377190.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  64. ^ Ichihashi M, Nagai H, Matsunaga K (2004). "Sunlight is an important causative factor of recurrent herpes simplex". Cutis. 74 (5 Suppl): 14–8. PMID 15603217.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  65. ^ Martinez V, Caumes E, Chosidow O (2008). "Treatment to prevent recurrent genital herpes". Curr Opin Infect Dis. 21 (1): 42–48. doi:10.1097/QCO.0b013e3282f3d9d3. PMID 18192785.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  66. ^ Sobngwi‐Tambekou J; Taljaard D; Lissouba P; et al. (2009). "Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa". J Infect Dis. 199 (7): 958–964. doi:10.1086/597208. PMC 2868899. PMID 19220143. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  67. ^ Koelle DM, Corey L (2008). "Herpes Simplex: Insights on Pathogenesis and Possible Vaccines". Annu Rev Med. 59: 381–395. doi:10.1146/annurev.med.59.061606.095540. PMID 18186706.
  68. ^ Smith JS, Robinson NJ (2002). "Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review". J. Infect. Dis. 186 Suppl 1: S3–28. doi:10.1086/343739. PMID 12353183.
  69. ^ Xu, Fujie (2006-10-23). "Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States". JAMA. 296 (8). AMA: 964–73. doi:10.1001/jama.296.8.964. PMID 16926356. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  70. ^ Xu, F (23). "Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14--49 Years --- United States, 2005--2008". Morbidity and Mortality Weekly Report (MMWR). 59 (15): 456–459. Retrieved 12 April 2011. {{cite journal}}: Check date values in: |date= and |year= / |date= mismatch (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  71. ^ a b c John Leo (1982-08-02). "The New Scarlet Letter". Time.
  72. ^ a b Chow AW; Roland A; Fiala M; et al. (1973). "Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients". Antimicrob. Agents Chemother. 3 (3): 412–7. PMC 444424. PMID 4790599. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  73. ^ Kaufman HE, Howard GM (1962). "Therapy of experimental herpes simplex keratitis". Invest Ophthalmol. 1: 561–4. PMID 14454441. {{cite journal}}: Unknown parameter |month= ignored (help)
  74. ^ Ch'ien LT, Whitley RJ, Alford CA, Galasso GJ (1976). "Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients: preliminary results of a collaborative study". J. Infect. Dis. 133 Suppl: A184–91. PMID 180198. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  75. ^ McKelvey EM, Kwaan HC (1969). "Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia". Blood. 34 (5): 706–11. PMID 5352659. {{cite journal}}: Unknown parameter |month= ignored (help)
  76. ^ Fiala M, Chow A, Guze LB (1972). "Susceptibility of Herpesviruses to Cytosine Arabinoside: Standardization of Susceptibility Test Procedure and Relative Resistance of Herpes Simplex Type 2 Strains". Antimicrob. Agents Chemother. 1 (4): 354–7. PMC 444221. PMID 4364937. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  77. ^ Allen LB; Hintz OJ; Wolf SM; et al. (1976). "Effect of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate on genital lesions and encephalitis induced by Herpesvirus hominis type 2 in female mice". J. Infect. Dis. 133 Suppl: A178–83. PMID 6598. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  78. ^ Juel-Jensen BE (1970). "Varicella and cytosine arabinoside". Lancet. 1 (7646): 572. doi:10.1016/S0140-6736(70)90815-9. PMID 4190397. {{cite journal}}: Unknown parameter |month= ignored (help)
  79. ^ Nahmias AJ, Kibrick S (1964). "INHIBITORY EFFECT OF HEPARIN ON HERPES SIMPLEX VIRUS". J. Bacteriol. 87 (5): 1060–6. PMC 277146. PMID 4289440. {{cite journal}}: Unknown parameter |month= ignored (help)
  80. ^ Allen LB, Sidwell RW (1972). "Target-Organ Treatment of Neurotropic Virus Diseases: Efficacy as a Chemotherapy Tool and Comparison of Activity of Adenine Arabinoside, Cytosine Arabinoside, Idoxuridine, and Trifluorothymidine". Antimicrob. Agents Chemother. 2 (3): 229–33. PMC 444296. PMID 4790562. {{cite journal}}: Unknown parameter |month= ignored (help)
  81. ^ Allen LB, Wolf SM, Hintz CJ, Huffman JH, Sidwell RW (1977). "Effect of ribavirin on Type 2 Herpesvirus hominis (HVH/2) in vitro and in vivo". Ann. N. Y. Acad. Sci. 284: 247–53. doi:10.1111/j.1749-6632.1977.tb21957.x. PMID 212976. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  82. ^ Allen LB, Cochran KW (1972). "Target-Organ Treatment of Neurotropic Virus Disease with Interferon Inducers". Infect. Immun. 6 (5): 819–23. PMC 422616. PMID 4404669. {{cite journal}}: Unknown parameter |month= ignored (help)
  83. ^ Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK; Khare; Witkowski (1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science. 177 (4050): 705–6. doi:10.1126/science.177.4050.705. PMID 4340949. {{cite journal}}: Missing |author2= (help); Missing |author4= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  84. ^ Babiuk LA, Meldrum B, Gupta VS, Rouse BT (1975). "Comparison of the Antiviral Effects of 5-Methoxymethyl-deoxyuridine with 5-Iododeoxyuridine, Cytosine Arabinoside, and Adenine Arabinoside". Antimicrob. Agents Chemother. 8 (6): 643–50. PMC 429441. PMID 1239978. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  85. ^ O'Meara A, Deasy PF, Hillary IB, Bridgen WD (1979). "Acyclovir for treatment of mucocutaneous herpes infection in a child with leukaemia". Lancet. 2 (8153): 1196. doi:10.1016/S0140-6736(79)92428-0. PMID 91931. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  86. ^ Whitley R; Arvin A; Prober C; et al. (1991). "A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group". N. Engl. J. Med. 324 (7): 444–9. doi:10.1056/NEJM199102143240703. PMID 1988829. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  87. ^ a b c Kimberlin DW; Lin CY; Jacobs RF; et al. (2001). "Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections". Pediatrics. 108 (2): 230–8. doi:10.1542/peds.108.2.230. PMID 11483782. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  88. ^ Mayou, R (1975). "Psychological morbidity in a clinic for sexually transmitted disease". The British journal of venereal diseases. 51 (1): 57–60. PMC 1045113. PMID 1173225.
  89. ^ "Journal of Clinical Investigation - Drug discovery in jeopardy". Jci.org. 2006-11-01. Retrieved 2011-04-12.
  90. ^ http://www.bmj.com/content/324/7342/886.1.full.pdf
  91. ^ Vezina C, Steben M. (2001). "Genital Herpes: Psychosexual Impacts and Counselling" (PDF). The Canadian Journal of CME (June): 125–34.
  92. ^ "Herpes FAQ". Herpesonline.org. Retrieved 2011-04-12.
  93. ^ "Genital Herpes: Living & Managing". Webmd.com. Retrieved 2011-04-12.
  94. ^ Green J, Ferrier S, Kocsis A, Shadrick J, Ukoumunne OC, Murphy S, Hetherton J. (2003). "Determinants of disclosure of genital herpes to partners". Sex. Transm. Infect. 79 (1): 42–44. doi:10.1136/sti.79.1.42. PMC 1744583. PMID 12576613.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  95. ^ Molecular Therapy (2006-05-01). "Molecular Therapy - Abstract of article: 801. RNA Gene Therapy Targeting Herpes Simplex Virus". Nature.com. Retrieved 2011-04-12.
  96. ^ "University of Florida News – Potential new herpes therapy studied". News.ufl.edu. 2009-02-03. Retrieved 2011-04-12.
  97. ^ Fox, Maggie (2008-07-02). "New approach offers chance to finally kill herpes". Reuters. Retrieved 2011-04-12.
  98. ^ Kingsbury, Kathleen (2008-07-02). "A Cure for Cold Sores?". Time. Retrieved 2010-05-04.
  99. ^ a b "Herpevac Trial for Women". Archived from the original on 2007-10-20. Retrieved 2008-03-04.
  100. ^ Jon Cohen (15 October 2010). "aPainful Failure of Promising Genital Herpes Vaccine". Science. 330 (6002): 304. doi:10.1126/science.330.6002.304.
  101. ^ http://www.acambis.com/default.asp-id=2052.htm
  102. ^ "FOCUS | March 7, 2008 | LICENSING: Herpes Vaccine Developed at HMS Licensed for Preclinical Trials".
  103. ^ Harvard Medical School: from Herpes Vaccines, 15. April 2011
  104. ^ BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine. See also: Your partner has herpes – now the good news from New Scientist.
  105. ^ Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B (2011). "A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine". PLoS ONE. 6 (3): e17748. doi:10.1371/journal.pone.0017748. PMC 3055896. PMID 21412438.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
Wikimedia Commons has media related to Herpes.

General

Images

Other

Retrieved from "https://en.wikipedia.org/w/index.php?title=Herpes&oldid=459594613"